Market News & Trends
Onconova Therapeutics Announces Initial Dosing of First Patient in US Phase 1 Clinical Trial
Onconova Therapeutics, Inc. recently announced the first patient has been dosed in the US Phase 1 clinical trial of ON 123300, the company’s proprietary, novel…
The Discovery Labs Signs Foundational Lease With the University of Pennsylvania Gene Therapy Program as Anchor Tenant
The Discovery Labs has recently signed a foundational lease with the University of Pennsylvania Gene Therapy Program (GTP), which will use Discovery Labs’ suburban campus…
CatalYm to Present Initial Data of First-in-Human Trial of GDF-15 Neutralizing Antibody CTL-002
CatalYm GmbH recently announced that their abstract with first interim data from the Phase 1 clinical trial investigation CTL-002 as monotherapy and in combination with…
Ajinomoto Bio-Pharma Services Expands Fill Finish Capacity With New Multi-Purpose Fill Suite
Ajinomoto Bio-Pharma Services recently announced it will soon open a high-speed multi-purpose fill finish line in its state-of-the-art commercial manufacturing facility located in San Diego,…
Phillips-Medisize Unveils Aria Smart Autoinjector Platform to Drive Innovation & Sustainability in Digital Drug Delivery
Phillips-Medisize, a Molex company and leader in drug delivery, diagnostic, and MedTech devices, recently unveiled the Aria Smart Autoinjector platform to unlock innovation, differentiation, and sustainability in the digital drug-delivery device market….
Biogen & Envisagenics Announce Collaboration to Advance RNA Splicing Research
Biogen Inc. and Envisagenics recently announced a new collaboration to advance ribonucleic acid (RNA) splicing research within central nervous system (CNS) diseases….
Mustang Bio & City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial
Mustang Bio, Inc. and City of Hope recently announced the first patient has been dosed in a clinical trial to establish the safety and feasibility…
Calithera Biosciences & Antengene Enter Worldwide License Agreement for Development & Commercialization of CB-708
Calithera Biosciences, Inc. and Antengene Corporation, Ltd. recently announced an exclusive, worldwide license agreement for the development and commercialization of CB-708, Calithera’s small….
Agenus & Bristol Myers Squibb Announce Exclusive Global License for Anti-TIGIT Bispecific Antibody Program
Bristol-Myers Squibb Company and Agenus Inc. recently announced they have entered into a definitive agreement under which Bristol Myers Squibb will be granted a global exclusive license to….
uniQure Presents HOPE-B Clinical Data Demonstrating Clinical Benefit in Hemophilia B Patients With Pre-existing Antibodies to AAV5 Vector
uniQure N.V. recently presented 26-week clinical data from the pivotal, Phase 3 HOPE-B gene therapy trial of etranacogene dezaparvovec showing clinical benefit in hemophilia B patients…
Ocuphire Granted Two New US Patents Covering Late-Stage Drug Candidate
Ocuphire Pharma, Inc. recently announced the United States Patent and Trademark Office (USPTO) has issued two patents covering the company’s late-stage product candidate, Nyxol (phentolamine…
Advicenne Receives Positive Feedback From US FDA on Pathway to Approval & Amended Phase 3 Study Protocol
Advicenne recemtly announced the US FDA acceptance of the amended protocol of the company’s US-based Phase 3 pivotal trial of ADV7103 (Sibnayal) for the treatment…
BD to Build New Manufacturing Facility in Spain to Support Ongoing Strong Growth of Prefilled Drug Delivery Business
BD (Becton, Dickinson and Company) recently announced will build a $200-million high-tech manufacturing facility in city of Zaragoza, located in the Aragon region of Spain,…
NovAliX Expands Cryo-Electron Microscopy Capabilities for Drug Development Offering
NovAliX recently announced the expansion of its cryogenic electron microscopy (cryo-EM) technology capability. NovAliX will benefit from the implementation at its premises of Thermo Fisher…
AC Immune Announces Expansion of Phase 1b/2a Phospho-Tau Alzheimer’s Vaccine Trial & Provides a Program Update
AC Immune SA recently announced the company and its strategic partner Janssen Pharmaceuticals, Inc. have expanded the ongoing Phase 1b/2a clinical trial of the companies’…
AzurRx BioPharma Announces Positive Interim Data in Phase 2 Clinical Trial
AzurRx BioPharma, Inc. recently announced positive interim data from the first 18 out of 20 patients in its Phase 2 trial evaluating MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (PERT),….
Checkpoint Therapeutics Announces Completion of Enrollment in the Registration-Enabling Trial of Cosibelimab
Checkpoint Therapeutics, Inc. recently announced the completion of enrollment for the metastatic cutaneous squamous cell carcinoma (cSCC) cohort in its registration-enabling clinical trial of….
New Adjuvanted Vaccine Candidate Using IDRI Formulation Demonstrates Coronavirus Pan-Vaccine Potential
The Infectious Disease Research Institute (IDRI), Duke Human Vaccine Institute, and 3M have collaborated to create a vaccine candidate with potential to provide protection against multiple variants of SARS-CoV-2….
Centogene Extends Global Parkinson’s Disease Study
Centogene N.V. recently announced it has extended the Rostock International Parkinson’s Disease (ROPAD) Study…..
Cybrexa Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial
Cybrexa Therapeutics recently announced the first patient has been dosed in a Phase 1/2 clinical trial evaluating CBX-12 (alphalex-exatecan), the company’s lead therapeutic candidate. The…
